What is Engrail Therapeutics, Inc.?
Headquartered in San Diego, California, Engrail Therapeutics, Inc. operates as a specialized neuroscience research enterprise. The company is dedicated to the discovery and development of novel therapeutic agents designed to mitigate the impact of diseases affecting the nervous system. By leveraging a sophisticated approach to drug discovery, Engrail aims to address significant unmet medical needs, positioning itself as a key player in the next generation of pharmaceutical innovation. The firm's market position is defined by its focus on high-impact, transformative medicines that target the underlying mechanisms of neurological dysfunction.
How much funding has Engrail Therapeutics, Inc. raised?
Engrail Therapeutics, Inc. has raised a total of $221M across 2 funding rounds:
Series A
$64M
Series B
$157M
Series A (2021): $64M with participation from Nan Fung Life Sciences
Series B (2024): $157M led by Forbion, Norwest Venture Partners, and F-Prime Capital Partners
Key Investors in Engrail Therapeutics, Inc.
Nan Fung Life Sciences
A global life sciences investment platform with a long-term capital commitment, specializing in company formation, venture capital, and drug discovery across all development stages.
Forbion
A global life sciences venture capital firm with a strong track record of guiding biotech and biopharmaceutical companies from early-stage research through clinical development.
F-Prime Capital Partners
A team of investors, engineers, and scientists dedicated to investing in healthcare and technology, providing deep domain expertise to support innovative medical companies.
What's next for Engrail Therapeutics, Inc.?
With the successful completion of its latest financing round, Engrail Therapeutics is poised to transition into a more intensive phase of clinical development. The strategic allocation of these funds will likely prioritize the advancement of lead candidates through human trials, while simultaneously bolstering the company's internal R&D infrastructure. As the firm scales its operations, the focus will remain on de-risking its pipeline and establishing proof-of-concept data that could serve as a catalyst for future partnerships or potential commercialization pathways. The company's ability to maintain its momentum in the neuroscience space will be critical as it navigates the complexities of late-stage drug development and regulatory milestones.
See full Engrail Therapeutics, Inc. company page
